Pln-101095

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

PLN-101095 is an experimental drug currently being studied in clinical trials. It is being investigated as a potential treatment for advanced or metastatic solid tumors, including colorectal cancer, in patients who have already received pembrolizumab and experienced disease progression. The goal of the clinical trials is to determine the safe dosage of PLN-101095 and to see if it has any effect on the cancer when given together with pembrolizumab. These are early-phase trials (Phase 1), primarily focused on safety and determining the right dose, rather than proving effectiveness. The trials are enrolling patients with advanced or metastatic solid tumors who have progressed after treatment with pembrolizumab.

Mechanism of Action

PLN-101095 is being studied in combination with pembrolizumab. Pembrolizumab is an immunotherapy drug that helps the body's immune system fight cancer by targeting PD-1. The specific mechanism of action of PLN-101095 is being investigated in clinical trials. It is being evaluated for its safety, how it is processed by the body (pharmacokinetics), its effect on the body (pharmacodynamics), and its potential preliminary anti-tumor activity.

Side Effects

Because PLN-101095 is an experimental drug in early-phase clinical trials (Phase 1) The full range of potential side effects is still being evaluated. The primary focus of Phase 1 trials is to assess safety and determine the maximum tolerated dose. Information about specific side effects observed in the trials is not yet widely available But common side effects associated with drugs in this class or used in combination with pembrolizumab can include fatigue Skin reactions Diarrhea Nausea And others. Patients participating in the trial will be closely monitored for any adverse events.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06270706 Phase 1
Recruiting
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
United States

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
786 trials
Leucovorin
Other Medications
647 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.